Canada - TSX:EDT - CA8475771033 - Common Stock
The current stock price of EDT.CA is 1.43 CAD. In the past month the price decreased by -0.69%. In the past year, price increased by 155.36%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 392.15M | ||
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 316.98M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 156.58M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 124.28M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 27 | 59.23M | ||
| NRX.CA | NUREXONE BIOLOGIC INC | N/A | 57.76M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 35.58M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.67M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 26.58M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 17.48M | ||
| MPH.CA | MEDICURE INC | N/A | 12.11M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 11.44M |
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The firm also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. The company provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.
SPECTRAL MEDICAL INC
135 The West Mall, Unit 2
TORONTO ONTARIO M9C 1C2 CA
CEO: Chris Seto
Employees: 29
Phone: 14166263233
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The firm also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. The company provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.
The current stock price of EDT.CA is 1.43 CAD. The price decreased by -2.72% in the last trading session.
EDT.CA does not pay a dividend.
EDT.CA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
EDT.CA stock is listed on the Toronto Stock Exchange exchange.
SPECTRAL MEDICAL INC (EDT.CA) operates in the Health Care sector and the Biotechnology industry.
SPECTRAL MEDICAL INC (EDT.CA) has a market capitalization of 411.75M CAD. This makes EDT.CA a Small Cap stock.
ChartMill assigns a technical rating of 9 / 10 to EDT.CA. When comparing the yearly performance of all stocks, EDT.CA is one of the better performing stocks in the market, outperforming 93.91% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to EDT.CA. EDT.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months EDT.CA reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS decreased by -17.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -388.99% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
5 analysts have analysed EDT.CA and the average price target is 3.16 CAD. This implies a price increase of 121.12% is expected in the next year compared to the current price of 1.43.
For the next year, analysts expect an EPS growth of 57.14% and a revenue growth 14.29% for EDT.CA